Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET
Rhea-AI Summary
Harvard Bioscience (Nasdaq: HBIO) will announce financial results for the quarter ended December 31, 2025 before the market opens on March 12, 2026.
The company will host an earnings conference call at 8:00 AM Eastern Time; registration is required for participants who wish to ask questions and an audio-only webcast will be available on the investor website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – HBIO
On the day this news was published, HBIO declined 0.46%, reflecting a mild negative market reaction. Argus tracked a peak move of +4.0% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $134K from the company's valuation, bringing the market cap to $29.07M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2025-10-30 | Earnings call scheduling | Neutral | +41.1% | Set Q3 2025 results release and call details before market open. |
| 2025-08-04 | Earnings call scheduling | Neutral | +10.9% | Announced Q2 2025 earnings date and 8:00 AM ET conference call. |
| 2025-05-05 | Earnings call scheduling | Neutral | -9.1% | Scheduled Q1 2025 results release and earnings conference call. |
| 2025-02-24 | Earnings call scheduling | Neutral | -6.0% | Announced Q4 2024 results timing and associated conference call. |
| 2024-10-29 | Earnings call scheduling | Neutral | +0.0% | Set Q3 2024 earnings release and call plans before market open. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Scheduling earnings conference calls (tagged “conferences,earnings”) has historically produced volatile but mixed reactions, with an average move of about 7.39% and both sharp gains and declines following otherwise neutral logistics announcements.
Over the last several quarters, Harvard Bioscience has repeatedly issued “conferences,earnings” notices to schedule quarterly results calls, typically before the market opens with an 8:00 AM ET start time. These logistics updates alone have sometimes led to large same-day stock moves, including a 41.1% gain on 2025-10-30 and a -9.06% decline on 2025-05-05. Today’s Q4 2025 call scheduling fits this recurring communication pattern, ahead of the planned March 12, 2026 results release.
Historical Comparison
In the past, HBIO issued 5 similar “conferences,earnings” notices with an average move of 7.39%, showing that simple scheduling updates have sometimes coincided with significant price swings.
The company has maintained a consistent cadence of quarterly earnings call scheduling, each time announcing pre-market releases and 8:00 AM ET calls as it cycles through Q1–Q4 reporting periods.
Regulatory & Risk Context
An effective S-3 resale registration dated 2026-01-30 covers up to 9,500,000 shares for selling securityholders, including warrant and convertible loan shares. The company itself would only receive up to $1.0 million if all $0.50 warrants are exercised for cash; it does not receive proceeds from resales of already-issued shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on March 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.
Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.
Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Company Contact:
Mark Frost
Interim Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com
